06-02-2012 13:40 Link: Stem Cell treatment overview of procedure YouTube - Video … Continue reading →

01-02-2012 13:37 Meet founders of Cord Blood Registry, Tom and Wendy. Hear why they started CBR -- a family business dedicated to helping people live healthier lives through cord blood stem cell medicine. Today, CBR has grown, but the attention to healthy families is the same. For more than 15 years, Cord Blood Registry has led the umbilical cord banking industry in technical innovations and provided families with peace of mind and hope. CBR's experience and dedication to quality has enabled CBR to help more clients use their cord blood stem cells in treatments than any other family bank. Our research and development efforts are focused on helping leading clinical researchers advance stem cell regenerative medicine that may help families in the future. Ultimate use of cord blood stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (like an HLA matched sibling). There is no guarantee that treatments being studied in the laboratory or in clinical trials will be available in the future. CBR is the preferred choice of OB/Gyns. © 2011 Cord Blood Registry. All rights reserved. Privacy Policy. … Continue reading →

07-02-2012 19:12 http://www.medi-post.com S. Korea approves sales of new stem cell drug (AFP) -- Jan 19, 2012 SEOUL — South Korea's government drug agency cleared the way Thursday for commercial sales of what it called the world's first approved medicine using stem cells collected from other people. Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns' umbilical cord blood, the Korea Food and Drug Administration said. "Cartistem is... the world's first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis," the administration said in a statement. Medipost said 27 billion won ($23.8 million) from private investors and government funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient's knees via surgery. Clinical trials have been under way in the United States since last year, the statement said. Two of the world's top 10 drugmakers are in talks to seek a worldwide licence to make the drug, a Medipost spokesman told AFP, adding that final trials involving a large number of people would likely begin in the US in 2015. Read … Continue reading →